Kumar A S
Department of Cardiothoracic & Vascular Surgery, All India Institute of Medical Sciences, New Delhi.
J Indian Med Assoc. 1999 Jul;97(7):282-6.
An estimated 3 million patients in India need treatment for valvular heart disease. Rheumatic heart disease continues to be the major aetiologic factor. The mitral valve is best conserved with valvotomy or repair. The aortic valve is difficult to repair and is best replaced by a biological substitute (autograft or homograft). The tricuspid valve can be repaired in all patients. Prosthetic valves offer good long term durability but introduce additional risks to the patients. Experience over the past three decades suggests that conservation of natural valve mechanism is currently the best option.
据估计，印度有300万患者需要接受心脏瓣膜病治疗。风湿性心脏病仍然是主要病因。二尖瓣通过瓣膜切开术或修复术能得到最佳保留。主动脉瓣难以修复，最好用生物替代品（自体移植或同种异体移植）进行置换。所有患者的三尖瓣都可以修复。人工瓣膜具有良好的长期耐用性，但会给患者带来额外风险。过去三十年的经验表明，保留自然瓣膜机制目前是最佳选择。
